Evidence map›Paper›PMID 32587964›Full record

ArticlebioRxiv : the preprint server for biology2020

Novel ACE2-IgG1 fusions with improved

Naoki Iwanaga, Laura Cooper, Lijun Rong, Brandon Beddingfield, Jackelyn Crabtree, Ralph A Tripp, Xuebin Qin, Jay K Kolls

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 45 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Naoki IwanagaDepartments of Pediatrics & Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Laura CooperDepartments of Microbiology and Immunology, College of Medicine University of Illinois at Chicago, Chicago, IL 60612 USA.
Lijun RongDepartments of Microbiology and Immunology, College of Medicine University of Illinois at Chicago, Chicago, IL 60612 USA.
Brandon BeddingfieldDepartments of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Jackelyn CrabtreeDepartments of Infectious Diseases, Animal Health Research Center, University of Georgia, Athens, GA 30602 USA.
Ralph A TrippDepartments of Infectious Diseases, Animal Health Research Center, University of Georgia, Athens, GA 30602 USA.
Xuebin QinDepartments of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Jay K KollsDepartments of Pediatrics & Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Tulane University · USUniversity of Georgia · USUniversity of Illinois Chicago · US

Funding

Training in CD4 T-cell Lung ImmunityR35HL139930 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KOLLS, JAY K · 2018 to 2024
$6.3M
Generation and Characterization of a Novel Cell Subpopulation Ablation ModelR21OD024931 · OD · TULANE UNIVERSITY OF LOUISIANA · PI QIN, XUEBIN · 2018 to 2019
$450k
NHLBI NIH HHS R35 HL139930NIAID NIH HHS HHSN272201400008CNIH HHS R21 OD024931
6 · The paper itself

Abstract

SARS-CoV2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. This fusion protein contained a LALA mutation that abrogates Fcrγ binding, but retains FcRN binding to prolong the half-life, as well as achieve therapeutic concentrations in the lung lavage. Interestingly, a mutation in the catalytic domain of ACE2, MDR504, completely abrogated catalytic activity, but significantly increased binding to SARS-CoV2 spike protein

Identifiers

PMID32587964
PMCPMC7310620
OpenAlexW3035118921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.